Related Experiment Video
Updated: Jul 10, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action
Anthony A Fossa1, Todd Wisialowski, J Neil Duncan
1Pfizer Global Research and Development, Department of Translational and Molecular Medicine, Groton, Connecticut 06340, USA. Anthony.a.fossa@pfizer.com
Abstract:
Prolongation of the electrocardiogram QT interval by some, but not all drugs, has been associated with increased incidence of sudden cardiac death. Current preclinical regulatory assays cannot discriminate the arrhythmia liability of these drugs. Consequently, many new medications that prolong the QT interval are not developed despite their potential therapeutic benefit. Alternans (action potential duration alternations) is a measure of cardiac instability in humans and animals associated with the onset of ventricular fibrillation. Due to potential arrhythmia risk from observed QT prolongation, alternans was assessed in the anesthetized guinea pig after azithromycin or chloroquine alone and after combination treatment at clinically relevant concentrations proposed for the management of malaria. Chloroquine alone, but not azithromycin, caused a profound increase in action potential duration but with only minimal effects on alternans (approximately 10 ms). Azithromycin alone and in combination with chloroquine showed no increase in alternans beyond vehicle baseline responses indicating no additional arrhythmia liability.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
